Evidence mapPaperPMID 35763133Full record

ArticleArchives of osteoporosis2022

Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group.

P Chotiyarnwong, E V McCloskey, N C Harvey, M Lorentzon, D Prieto-Alhambra, B Abrahamsen, J D Adachi, F Borgström, O Bruyere, J J Carey and 20 more

Abstract readConsensus Statement
In one paragraph

Article in Archives of osteoporosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Pooled it
  2. Family history of fracture and fracture risk: a meta-analysis to update the FRAX® risk assessment tool.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Pooled it
  3. Updated practice guideline for dual-energy X-ray absorptiometry (DXA).European journal of nuclear medicine and molecular imaging · 2025
    Guideline
  4. Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Optimisation of vitamin D status in global populations.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Review
  14. Article
  15. Article
  16. The yield of routine laboratory examination in osteoporosis evaluation in primary care.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  17. Review
  18. Article
  19. Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

P ChotiyarnwongDepartment of Oncology & Metabolism, Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK.
E V McCloskeyDepartment of Oncology & Metabolism, Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK. e.v.mccloskey@sheffield.ac.uk.
N C HarveyMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
M LorentzonUniversity of Gothenburg, Gothenburg, Sweden.
D Prieto-AlhambraOxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
B AbrahamsenDepartment of Clinical Research, Odense Patient Data Exploratory Network, University of Southern Denmark, Odense, Denmark.
J D AdachiDepartment of Medicine, Michael G DeGroote School of Medicine, St Joseph's Healthcare-McMaster University, Hamilton, ON, Canada.
F BorgströmQuantify Research, Stockholm, Sweden.
O BruyereWHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
J J CareySchool of Medicine, National University of Ireland Galway, Galway, Ireland.
P ClarkClinical Epidemiology Unit of Hospital Infantil de México Federico Gómez-Faculty of Medicine, Universidad Nacional Autónoma de México, UNAM, Mexico City, Mexico.
C CooperMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
E M CurtisMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
E DennisonMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
M Diaz-CurielHospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
H P DimaiDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
D GrigorieCarol Davila University of Medicine, Bucharest, Romania.
M HiligsmannDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands.
P KhashayarCenter for Microsystems Technology, Imec and Ghent University, 9050, Ghent, Belgium.
E M LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.
P LipsDepartment of Internal Medicine, Endocrine Section & Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
R S LorencMultidisciplinary Osteoporosis Forum, SOMED, Warsaw, Poland.
S OrtolaniIRCCS Istituto Auxologico, UO Endocrinologia E Malattie del Metabolismo, Milano, Italy.
A PapaioannouDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
S SilvermanCedars-Sinai Medical Center, Los Angeles, CA, USA.
M SosaBone Metabolic Unit, University of Las Palmas de Gran Canaria, Hospital University Insular, Las Palmas, Gran Canaria, Spain.
P SzulcINSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Lyon, France.
K A WardMRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
N YoshimuraDepartment of Preventive Medicine for Locomotive Organ Disorders, 22Nd Century Medical and Research Center, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
J A KanisCentre for Metabolic Bone Diseases, Northern General Hospital, University of Sheffield, Herries Road, Sheffield, S5 7AU, UK.

Funding

Medical Research Council G0400491Medical Research Council MC_PC_21000Medical Research Council MC_PC_21001Medical Research Council MC_PC_21003Medical Research Council MC_PC_21022Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12011/2Medical Research Council MR/P020941/1MRF_ MRF-145-0011-DG-HARV-C0913Versus Arthritis 19583
6 · The paper itself

Abstract

The IOF Epidemiology and Quality of Life Working Group has reviewed the potential role of population screening for high hip fracture risk against well-established criteria. The report concludes that such an approach should strongly be considered in many health care systems to reduce the burden of hip fractures.

introductionThe burden of long-term osteoporosis management falls on primary care in most healthcare systems. However, a wide and stable treatment gap exists in many such settings; most of which appears to be secondary to a lack of awareness of fracture risk. Screening is a public health measure for the purpose of identifying individuals who are likely to benefit from further investigations and/or treatment to reduce the risk of a disease or its complications. The purpose of this report was to review the evidence for a potential screening programme to identify postmenopausal women at increased risk of hip fracture.

methodsThe approach took well-established criteria for the development of a screening program, adapted by the UK National Screening Committee, and sought the opinion of 20 members of the International Osteoporosis Foundation's Working Group on Epidemiology and Quality of Life as to whether each criterion was met (yes, partial or no). For each criterion, the evidence base was then reviewed and summarized. RESULTS AND

conclusionThe report concludes that evidence supports the proposal that screening for high fracture risk in primary care should strongly be considered for incorporation into many health care systems to reduce the burden of fractures, particularly hip fractures. The key remaining hurdles to overcome are engagement with primary care healthcare professionals, and the implementation of systems that facilitate and maintain the screening program.

Indexed as

Hip FracturesOsteoporosisFemaleHumansMass ScreeningPostmenopauseQuality of LifeCost-effectivenessFracture riskFRAXScreeningTreatment

Identifiers

PMID35763133
PMCPMC9239944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.